Document is current

Article History

Received: 6 October 2024

Revised: 12 November 2024

Accepted: 15 November 2024

First Online: 16 December 2024

Declarations

:

: AS received research support from Swiss Heart Foundation and TEVA pharmaceuticals. MB reports research support from the Department of Neurology, Inselspital, and the University of Bern, Switzerland. TRM reports grants from the Bangerter-Rhyner Foundation, the Baasch-Medicus Foundation, the University of Bern, the Swiss National Science Foundation and the Swiss Heart Foundation. MA reports speaker honoraria from Astra Zeneca, Bayer, Covidien, Medtronic, Sanofi and honoraria for scientific advisory boards from Amgen, Bayer, BMS, Daiichi Sankyo, Medtronic, Pfizer, and research funding from the Swiss National Science Foundation (SNSF), and the Swiss Heart Foundation (SHF). UF reports financial support for the SWIFT DIRECT trial (Medtronic), research grants from Medtronic BEYOND SWIFT registry, SNSF, SHF, consulting fees from Medtronic, Stryker and CSL Behring (fees paid to institution); membership of a Data Safety Monitoring Board for the IN EXTREMIS trial and TITAN trial and Portola (Alexion) Advisory board (fees paid to institution). HPM was neurology principal investigator of the PC-Trial, was member of the steering committee of the PRIMA Trial, and reports consultancy fees from Medtronic, Stryker and Cerenovus. JO owns stock in Novo Nordisk, Moberg Pharma and Cephagenix. SJ reports grants from the Swiss National Science Foundation and the Swiss Heart Foundation. CJS reports consulting, Advisory Boards, Speaker, Travel Support for/from Abbvie, Allergan, Almirall, Amgen, Eli Lilly, Grnenthal, Lundbeck, MindMed, Novartis, Pfizer and TEVA Pharmaceuticals. All other authors have nothing to disclose.